thalidomide has been researched along with Osteoporosis in 4 studies
Thalidomide: A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppressive and anti-angiogenic activity. It inhibits release of TUMOR NECROSIS FACTOR-ALPHA from monocytes, and modulates other cytokine action.
thalidomide : A racemate comprising equimolar amounts of R- and S-thalidomide.
2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione : A dicarboximide that is isoindole-1,3(2H)-dione in which the hydrogen attached to the nitrogen is substituted by a 2,6-dioxopiperidin-3-yl group.
Osteoporosis: Reduction of bone mass without alteration in the composition of bone, leading to fractures. Primary osteoporosis can be of two major types: postmenopausal osteoporosis (OSTEOPOROSIS, POSTMENOPAUSAL) and age-related or senile osteoporosis.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The methods used in treatment of osteoporosis induced by glucocorticosteroids are not effective enough." | 1.38 | Effects of thalidomide on the development of bone damage caused by prednisolone in rats. ( Kaczmarczyk-Sedlak, I; Rotko, K; Sedlak, L; Zych, M, 2012) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (25.00) | 18.2507 |
| 2000's | 1 (25.00) | 29.6817 |
| 2010's | 2 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Otto, S | 1 |
| Schreyer, C | 1 |
| Hafner, S | 1 |
| Mast, G | 1 |
| Ehrenfeld, M | 1 |
| Stürzenbaum, S | 1 |
| Pautke, C | 1 |
| Kaczmarczyk-Sedlak, I | 1 |
| Zych, M | 1 |
| Rotko, K | 1 |
| Sedlak, L | 1 |
| Hess, U | 1 |
| McCarty, MF | 1 |
1 review available for thalidomide and Osteoporosis
| Article | Year |
|---|---|
[The plasma cell myeloma--molecular pathogenesis and target therapies].
Topics: Aged; Angiogenesis Inhibitors; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols | 2006 |
3 other studies available for thalidomide and Osteoporosis
| Article | Year |
|---|---|
Bisphosphonate-related osteonecrosis of the jaws - characteristics, risk factors, clinical features, localization and impact on oncological treatment.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protoc | 2012 |
Effects of thalidomide on the development of bone damage caused by prednisolone in rats.
Topics: Administration, Oral; Animals; Bone Remodeling; Dose-Response Relationship, Drug; Femur; Glucocortic | 2012 |
Thalidomide may impede cell migration in primates by down-regulating integrin beta-chains: potential therapeutic utility in solid malignancies, proliferative retinopathy, inflammatory disorders, neointimal hyperplasia, and osteoporosis.
Topics: Animals; Antineoplastic Agents; Callithrix; Fish Oils; Gene Expression; Humans; Hyperplasia; Inflamm | 1997 |